Skip to main content

Advertisement

Table 1 Comparison of baseline clinical characteristics of patients with newly diagnosed metastatic colorectal cancer stratified by pre-treatment lymphocyte-to-monocyte ratio (LMR)

From: Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Characteristic LMR < 3.11 [cases (%)] LMR ≥ 3.11 [cases (%)] P value
Total 216 272  
Gender 0.817
 Male 119 (55.1) 147 (54.0)  
 Female 97 (44.9) 125 (46.0)
Age (years) 0.802
 <60 139 (64.4) 178 (65.4)  
 ≥60 77 (35.6) 94 (34.6)
ECOG performance status 0.013
 <2 126 (58.3) 188 (69.1)  
 ≥2 90 (41.7) 84 (30.9)
Site of primary tumor 0.907
 Colon 114 (52.8) 145 (53.3)  
 Rectum 102 (47.2) 127 (46.7)
No. of metastatic sites <0.001
 ≤2 157 (72.7) 118 (43.4)  
 >2 59 (27.3) 154 (56.6)
Tumor differentiation <0.001
 Well or moderate 163 (75.5) 120 (44.1)  
 Poor 53 (24.5) 152 (55.9)
Pre-chemotherapy ALC (×109/L)  
 <2.70 122 (56.5) 107 (39.3)  
 ≥2.70 94 (43.5) 165 (60.7)
Pre-chemotherapy AMC (×109/L) <0.001
 <0.55 57 (26.4) 128 (47.1)  
 ≥0.55 159 (73.6) 144 (52.9)
  1. ALC absolute lymphocyte count, AMC absolute monocyte count, ECOG Eastern Cooperative Oncology Group